InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-42.0%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Hoberman Kenneth, Director. Insider active across 3 companies, notably TG Therapeutics, INC.. Aggregated, 10 disclosures have been logged. Breakdown: 1 buy · 0 sell. Total volume traded: €101k. Activity tracked since 18 June 2021. The latest transaction was disclosed on 12 June 2025 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Hoberman Kenneth
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations10 total
14,718 shares0Common StockSEC:0001437749-25-020543:0
30,000 shares0Common StockSEC:0001104659-25-058915:0
22,250 shares0Common StockSEC:0001437749-24-020849:0
30,000 shares0Common StockSEC:0001104659-24-071285:0
20,000 shares0Common StockSEC:0001104659-23-105394:0
18,000 shares0Common StockSEC:0001104659-23-072605:0
43,732 shares0Common StockSEC:0001104659-22-082020:0
6,000 shares@ US$17.40100.0% of flowCommon StockSEC:0001104659-22-060913:0
Canonical exit: 10 Aug 2022 (T+90)
20,000 shares0COMMON STOCKSEC:0001104659-21-084258:0
150,000 sharesCommon StockSEC:0001104659-16-089212:0
10 of 10 declarations
About Hoberman Kenneth
Hoberman Kenneth is Administrateur at TG Therapeutics, INC. and Nuvectis Pharma, Inc., and Chief Operating Officer at STEMLINE THERAPEUTICS INC. He has 10 filings in total, and across the 10 sampled filings, the period runs from 2016-01-11 to 2025-06-16, with EUR 100582 of purchases and EUR 0 of sales, and the most frequent transaction nature is Attribution.
